glp 1 and inflammation GLP-1 Receptor Agonists Reduce A surprising role for enteroendocrine
Description
Semaglutide at higher doses (2.4 mg weekly) has shown the most robust evidence for NASH resolution in clinical trials, achieving resolution in 59% of patients
Endogenous hyperinsulinemia may cause weight gain and obesity [30], and treatment with insulin causes substantial weight gain, and may even increase cardiovascular risk [31]
For those on GLP-1 medications, dietary fibre is important for preventing constipation together with adequate hydration
Ozempic is considered a first-line treatment for Type 2 diabetes only if you have cardiovascular disease (CV disease) or are at high risk for CV disease
